Gadolinium and nephrogenic systemic fibrosis: time to tighten practice

Abstract

Nephrogenic systemic fibrosis (NSF) is a relatively new entity, first described in 1997. Few cases have been reported, but the disease has high morbidity and mortality. To date it has been seen exclusively in patients with renal dysfunction. There is an emerging link with intravenous injection of gadolinium contrast agents, which has been suggested as a main triggering factor, with a lag time of days to weeks. Risk factors include the severity of renal impairment, major surgery, vascular events and other proinflammatory conditions. There is no reason to believe that children have an altered risk compared to the adult population. It is important that the paediatric radiologist acknowledges emerging information on NSF but at the same time considers the risk:benefit ratio prior to embarking on alternative investigations, as children with chronic kidney disease require high-quality diagnostic imaging.

DOI: 10.1007/s00247-007-0633-8

Extracted Key Phrases

1 Figure or Table

0200040002008200920102011201220132014201520162017
Citations per Year

7,147 Citations

Semantic Scholar estimates that this publication has 7,147 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Mendichovszky2007GadoliniumAN, title={Gadolinium and nephrogenic systemic fibrosis: time to tighten practice}, author={Iosif A. Mendichovszky and Stephen D. Marks and Clare M. Simcock and \Oystein E. Olsen}, journal={Pediatric Radiology}, year={2007}, volume={38}, pages={489 - 496} }